For oncology clinicians, staying informed about the latest research and data leads to better care for the more than 1 million people who have blood cancer or are in remission.

As the field of hematologic malignancies continues to rapidly evolve, the new Leukemia, Lymphoma & Myeloma Winter Symposium stands out as a premier event for healthcare professionals seeking to enhance their knowledge and skills with the latest research updates.

The eagerly awaited symposium is an extension of the flagship Lymphoma, Leukemia & Myeloma (LL&M) Congress. LL&M Winter will be held February 7-9, 2025 in Miami Beach, and promises a robust program filled with the latest published data of the recent national and international conferences on in-depth sessions that will cover the latest advances in diagnosing and treating blood cancers.

Healthcare professionals specializing in hematologic oncology can start 2025 by getting the latest clinical data updates from recent hematology/oncology conferences across the globe, all over three days in sunny Miami Beach, Florida.

For oncology clinicians, staying informed about the latest research and data leads to better care for the more than 1 million people who have blood cancer or are in remission. Keeping up with the sheer volume of information can be challenging, but the LL&M Winter Symposium is designed to make it more manageable.

Expect a dynamic exchange of ideas and practical insights on how emerging scientific evidence will influence clinical practice in an information-packed three days. Building on the 25-year legacy of the annual LL&M Congress, this symposium’s educational program will translate the latest research and updates from recent global hematology and oncology conferences into actionable practices.

The agenda includes data-driven presentations, expert-led case studies, and interactive discussions to improve clinical outcomes. This event is dedicated to synthesizing the latest clinical data updates in Leukemia, CLL, Multiple Myeloma, and Lymphoma, and sharing top-line, clinically relevant information with our community of healthcare professionals.

The educational program includes:

• Leukemia Landscape: Research and Clinical Advances, on February 7, featuring updates in the diagnosis and classification of myeloid malignancies, low/intermediate-risk and high-risk myelodysplastic syndromes, chronic myeloid leukemia, myeloproliferative neoplasms, acute lymphoblastic leukemia, acute myeloid leukemia, and improving clinical decisions;
   
• Myeloma and CLL Landscape: Research and Clinical Advances, on February 8, spotlighting chronic lymphocytic leukemia with programs on bispecific antibodies, degraders, CAR-T cells, BTK resistance and mutations and more. That afternoon, the multiple myeloma landscape will be explored through sessions on precursor disorders, diagnosis, pathophysiology, transplants, refractory CAR-T therapy, relapses, refractory bispecific antibody treatment and more; and
   
• Lymphoma Landscape: Research and Clinical Advances, on February 9, including diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, follicular lymphoma, Hodgkin’s lymphoma and relapses.

Another key benefit of attending the LL&M Winter Symposium is the opportunity to connect with peers and thought leaders in the field. Networking sessions will allow participants to share insights, discuss challenges, and forge valuable collaborations that can enhance their professional development.

Throughout the LL&M Winter Symposium, interactive Q&A sessions will encourage interaction among faculty and attendees. Social events include a welcome reception the evening of February 7 and a networking reception on February 8.

The LL&M Winter Symposium will place attendees at the forefront of hematologic malignancy research and treatment. Whether you are a clinician, researcher, allied health professional, advanced practice provider, student or pharmaceutical industry specialist, this symposium offers invaluable resources and knowledge that can directly impact patient care.

Registration for the LL&M Winter Symposium is available with early discounts ending January 10. Don’t miss the chance to be part of this exciting gathering that will take your expertise in hematologic malignancies to the next level.

Dr. Morton Coleman is a world-renowned medical hematologist-oncologist who has specialized in the treatment of patients with lymphoma, multiple myeloma, leukemia, and Hodgkin and non-Hodgkin lymphoma, Chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. He shares his expertise through clinical professorships and as a member and chairman of numerous medical and scientific committees. He has published extensively on these entities and has served as chairman or member of numerous prestigious medical and scientific organizations.